Key clinical point: Apixaban surpassed two other direct-acting oral anticoagulants in a large, observational database.
Major finding: The adjusted stroke or systemic embolism rate with apixaban was 35% less than dabigatran and 28% less than rivaroxaban.
Study details: A retrospective analysis of observational data collected in insurance claims from 53,710 U.S. octogenarians.
Disclosures: The study was funded by Bristol-Myers Squibb and Pfizer, the companies that market apixaban (Eliquis). Dr. Deitelzweig is a consultant to and speaker on behalf of Bristol-Myers Squibb and Pfizer. He is also a consultant to or speaker on behalf of Boehringer Ingelheim, Daiichi-Sankyo, Janssen, and Portola Pharmaceuticals.
Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900
This Week's Must Reads
Must Reads in Thrombosis
TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885